Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 25 February 2015 | By Alexander Gaffney, RAC,
For one dietary supplement company warned by the US Food and Drug Administration (FDA) this week, regulatory compliance has something in common with what the company claims its "male enhancement" product will do to users: It's hard.
The Warning Letter—among the very few we've ever read to include explicit language—calls out Biogenix USA, a Mississippi- and Georgia-based company inspected by FDA in 2013. During the inspection, FDA said it collected "product labels and samples" of the company's products.
Subsequent laboratory testing by FDA confirmed the products contained active pharmaceutical ingredients, including tadalafil and verdenafil—both active ingredients in the FDA-approved erectile dysfunction medications Cialis and Levitra.
The inclusion of FDA-approved drugs in a supplement causes them to become drugs under the Federal Food, Drug and Cosmetic Act (FD&C Act), FDA noted.
"According to section 201(ff)(3)(B)(ii) of the FDCA [21 U.S.C. § 321 (ff)(3)(B)(ii)], a dietary supplement also may not include an article authorized for investigation as a new drug for which substantial clinical investigations have been instituted and made public, unless the article was marketed as a dietary supplement or food before its authorization as a new drug," the agency wrote in its letter, which was posted to FDA's website on 24 February 2015.
Regulators' concerns about the company extend beyond its ingredients, however. FDA found the company's labels included statements that the products would make users "hard as a mother**cker" and should be taken "prior to sexual activity."
Even if the products didn't contain prescription drug ingredients, these claims alone would have caused the supplements to become drugs because they are intended for conditions requiring licensed medical supervision, FDA said.
The company also failed to exercise proper oversight of its manufacturing operations, FDA claimed in the Warning Letter.
FDA Warning Letter to Biogenix USA
Tags: Warning Letter, Compliance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.